Cocrystal Pharma

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP net loss of $3.16M ($0.23 per share) vs. an expected loss of $2.50M ($0.165 per share). While government contract revenue of $105K exceeded the zero-revenue expectation, operating expenses surged 56% YoY, driven by the commencement of the Phase 1b Norovirus challenge study. Cash position remains critical at $2.17B as of June 30, though partially mitigated by a $5M post-quarter strategic investment from OPKO Health.